Axonal transport, protein trafficking and neurological disease

目前还没有有效的治疗运动神经元疾病/肌萎缩侧索硬化症。事实上，肌萎缩性侧索硬化症患者运动神经元死亡的机制甚至还没有得到很好的理解。然而，在该疾病模型中发现的最早缺陷之一是蛋白质在细胞中的运动被一种称为？轴突运输?。轴突运输缺陷也见于其他神经退行性疾病。因此，这项研究计划是为了深入了解轴突运输在ALS中受损的机制。我们会以不同方式向公众公布我们的调查结果。首先，克里斯·米勒和克里斯·肖定期在运动神经元疾病协会会议上向病人和护理人员的外行听众讲述他们的研究。Chris Shaw还通过广播和电视向公众传播关于ALS的研究成果和策略。此外，IOP还举办开放日（由MRC资助），通过一系列的讲座和实践研究报告，公众成员可以接触到IOP目前正在进行的广泛的神经退行性疾病相关研究项目。最后，我们的研究结果被列在IOP的网页上，并通过IOP新闻办公室进行曝光。

There are currently no effective treatments for motor neuron disease/amyotrophic lateral sclerosis. Indeed, the mechanisms by which motor neurons die in ALS are not even properly understood. However, one of the earliest defects seen in models of the disease is disruption to movement of proteins through the cell by a process termed ?axonal transport?. Defective axonal transport is also seen in several other neurodegenerative diseases. This programme of studies is therefore to gain insight into the mechanisms by which axonal transport is damaged in ALS. We will disseminate our findings to the public in a variety of ways. Firstly, both Chris Miller and Chris Shaw regularly speak to lay audiences of patients and carers on their research at Motor Neurone Disease Association meetings. Chris Shaw has also communicated research findings and strategies on ALS to the public via radio and television broadcasts. In addition, the IOP hosts Open Days (which have been funded by the MRC) in which members of the public, through a series of talks and hands-on research presentations, are exposed to the wide range of neurodegenerative diseases-related research projects that are currently underway in the IOP. Finally, our findings are listed on the IOP WEB pages and receive exposure through the IOP press office.